Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.
Open original source
The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.
Open original source